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Introduction: Taxanes have demonstrated effectiveness in the treatment of breast cancer, the most common type
of cancer in women. The toxicity profile of taxanes (including skin toxicities) induces dose adjustment, delay, or
discontinuation, which prevents a sufficient dose intensity to achieve a response. Nanoparticle albumin-bound
paclitaxel, a solvent-free form of paclitaxel, prevents toxicities and reduces the pharmacokinetic interferences
between paclitaxel and other drugs.
Case presentation: We describe the case of a 55-year-old Caucasian woman with locally advanced breast cancer
treated with neoadjuvant therapy who developed secondary skin toxicity due to delayed hypersensitivity to taxanes.
She received Adriamycin® (doxorubicin), cyclophosphamide and docetaxel and developed toxicity that promoted
treatment delay and a switch to weekly paclitaxel. After the third and fourth weeks of treatment, paclitaxel toxicities
also induced treatment delay and paclitaxel was switched to nanoparticle albumin-bound paclitaxel. She completed
the five planned nanoparticle albumin-bound paclitaxel cycles with acceptable tolerability (including persistent
grade 2 neuropathy) and without dose delay or adjustments. Clinical response was achieved although pathological
response was not good.
Conclusions: Nanoparticle albumin-bound paclitaxel treatment is a good option for patients with breast cancer
with taxanes-related skin toxicity. This drug allows the treatment to be completed with acceptable tolerance in our
case.
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Breast cancer is the most common type of cancer diag-
nosed in women [1]. Breast cancer is a heterogeneous dis-
ease regarding gene expression, morphology, clinical course
and treatment response [2].
Taxanes have shown significant activity in early and ad-
vanced breast cancer [3]. Due to the hydrophobic pro-
perties of taxanes, solvents are required for intravenous
administration (Tween 80® and Cremophor®) [4]. Solvents* Correspondence: bcirauqui@iconcologia.net
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reproduction in any medium, provided the orlimit the clinical effectiveness of taxanes, induce a toxic
response [2] and increase the adverse effects experienced
by patients with breast cancer, such as myelosuppression,
neurotoxicity, arthralgia and/or myalgia, and hypersensi-
tivity reactions. It has been shown that Cremophor® used
as a solvent in paclitaxel is associated with major side
effects including neutropenia, hypersensitivity reactions,
and neuropathy due to axonal degeneration. Tween 80®,
the solvent used in docetaxel, has been shown to partially
contribute to fluid retention by altering membrane fluid-
ity. These toxicities often require dose delay, adjustment
or even discontinuation of taxanes.
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel;
Abraxane®) is a solvent-free form of paclitaxel, whichl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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solvent-based paclitaxel prevents toxicities such as hyper-
sensitivity reactions and long-standing neuropathy, reduces
the pharmacokinetic interferences between paclitaxel and
other drugs, and decreases the complexity and inconve-
niences of paclitaxel dosing [5].
We here discuss a case of a patient who received taxanes
and developed skin toxicity; the taxanes were replaced by
nab-paclitaxel, which allowed her to complete her neoad-
juvant chemotherapy schedule.
Case presentation
A 55-year-old Caucasian postmenopausal woman with a
history of penicillin allergy, dyslipidemia with hypolipid-
emic diet treatment and no substance abuse, was re-
ferred to our Breast Pathology Unit when a left axillary
lymph node was noted on palpation.
The examination revealed a hard fixed matted lymph
node mass of 5×3.5cm on her left axilla, and a 1×1cm
lump in her left breast axillary tail. The mammography
showed a 20 to 24mm, dense, well-defined left breast
nodule (upper external quadrant), and dense well-
defined nodules in the left axillary space, the largest one
measuring 4 to 5cm. In addition, an ultrasound scan re-
vealed a 2cm well-defined, hypo to anechoic nodule in
the upper outer quadrant of her left breast tail. The left
axillary nodules were abnormally enlarged lymph nodes,
all of them hypoechoic with cortical thickening. Eccen-
tric hilum was absent in some of the nodes.
The examination was completed with a magnetic res-
onance imaging (MRI) of her breasts, which detected a
lesion at the junction of the outer quadrants, close to
the retroareolar region of her left breast. The lesion had
undefined margins and two adjacent areas of focal up-
take measuring 2×1.7×2cm, and multiple enlarged left
axillary lymph nodes extending from her breast tail to
levels I and II.
A biopsy of the retroareolar area was consistent with
infiltrating lobular carcinoma, 100% of the tumor cells were
positive for estrogen receptor, negative for progesteroneFigure 1 Grade 3 skin toxicity secondary to docetaxel.receptors (PR) and without overexpression of c-erbB-2
(score 1).
A needle biopsy from two of the enlarged axillary
lymph nodes and the enlarged intramammary lymph
node in her breast tail was consistent with metastasis of
carcinoma.
The staging evaluation showed no evidence of distant
spread.
Neoadjuvant chemotherapy was administered based
on the high burden of axillary disease and the risk of
microscopic dissemination, and on the hormone status
(PR negative) that suggested a luminal B tumor type
which is likely to benefit from chemotherapy and evi-
dence of response after neoadjuvant chemotherapy in
lobular-type tumor [6]. The patient received four cycles
of Adriamycin® (doxorubicin, 60mg/m2) and cyclophos-
phamide (600mg/m2) every 3 weeks, achieving partial re-
sponse on physical examination. Docetaxel (100mg/m2)
was started subsequently, with cycles every 21 days for 4
planned courses.
After cycle 1, the patient developed grade 3 skin toxicity
(with a predominance of erythrodysesthesia on the soles
of her feet and on the palms and dorsa of her hands),
grade 3 arthralgia and myalgia, and grade 2 asthenia
(Figure 1). This significant toxicity promoted a 1-week
chemotherapy delay. Symptoms were managed with
anti-inflammatory drugs and oral and topical steroids;
signs and symptoms improved to grade 1.
Subsequently, the severity of the skin toxicity associated
with docetaxel involved treatment-switching to paclitaxel
80mg/m2 weekly. After the first week of this treatment
neither new toxicities occurred nor pre-existing toxicities
increased. After the second week, the patient developed
paclitaxel toxicities that included grade 1 diarrhea and
grade 1 peripheral neuropathy.
Tolerability of treatment decreased after the third
week of paclitaxel, and toxicities included grade 2 asthe-
nia, grade 2 peripheral neuropathy, grade 2 diarrhea,
and grade 2 skin and nail toxicity. These toxicities pro-
moted chemotherapy delay and she was treated with
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The fourth dose of paclitaxel was administered 1 week
later; the patient developed the same symptoms and the
treatment required a further delay.
As a consequence of her symptoms and the importance
of chemotherapy dose intensity in the neoadjuvant setting,
paclitaxel was switched to nab-paclitaxel 100mg/m2 weekly.
Standard paclitaxel would have required a dose reduction
or further delays in treatment (Figure 2).
Tolerability was acceptable with resolution of diarrhea,
improvements in skin toxicity and asthenia to grade 1,
and persistence of grade 2 neuropathy. She completed
the five planned weeks of treatment without delays or
dose adjustment.
Post-treatment breast imaging with mammography,
ultrasound, and posterior MRI, showed complete response
of the retroareolar lesion and partial response of the en-
larged intramammary lymph node and axillary lymph
nodes.
As a result of this good response, tumorectomy with
axillary lymph node removal were performed. Histology
showed infiltrating lobular carcinoma measuring 1.5cm
with lower anterior and posterior margins involved, and
metastases from infiltrating lobular carcinoma with pleo-
morphic areas and signet ring cells in 20/20 isolated
lymph nodes, the largest one measuring 2cm in longest
diameter.
As margins were involved, a mastectomy was performed
at a second stage and no residual malignancy was found.
Discussion
The use of taxanes has been associated with a number
of skin toxicities. With paclitaxel, administration site re-
actions are generally rare and mild, ranging from ery-
thema or phlebitis to depigmentation. Paclitaxel is
considered irritating rather than vesicant, and lesions
from extravasation are usually mild; however, edema,
cellulitis, and even necrosis have also been reported. An-
other type of skin toxicity is the “recall effect”, both in
previously irradiated areas and in extravasation sites.
Some isolated cases of nail bed ulceration have also beenFigure 2 Improvement of skin toxicity during treatment with nanopanotified. Hypersensitivity reactions, both acute (charac-
terized by skin rash) and delayed (in the form of blisters,
diffuse pustular rash with exfoliation, pruritic maculo-
papular rash, scleroderma-like lesions, or hand-foot syn-
drome) have been reported [7-10].
With docetaxel treatment, most patients develop some
type of skin toxicity, which is usually mild and self-
limited. These reactions include hypersensitivity, edema,
erythrodysesthesia, erythema multiforme, nail changes,
photosensitivity, scleroderma, and subacute cutaneous
lupus erythematosus [10-12].
These skin toxicities secondary to taxanes seem to be
immune-mediated. Both acute and chronic hypersensi-
tivity reactions may be secondary to the cytotoxic agent
itself or to any of its additives. Cremophor® has been re-
ported to be involved not only in hypersensitivity reactions
but also in changes in the pharmacokinetics of paclitaxel.
Due to the toxic effects reported, the dose of paclitaxel
and docetaxel that can be administered is limited. In
chemotherapy, dose intensity is a well-known major de-
termining factor in the prognosis of patients with breast
cancer, and even a linear relationship between both was
identified [13]. Bonadonna et al. reported that the re-
sponse rate to primary chemotherapy is probably more
related to dose intensity than to the chemotherapy regi-
men itself [14]. The importance of achieving complete
response is also well established in the neoadjuvant set-
ting for long-term prognosis, with lower relapse rate and
increased overall survival [15].
Nab-paclitaxel has shown good clinical results in first-
and further-line therapy of patients with metastatic breast
cancer (MBC) and it has also demonstrated considerable
activity in taxane-pretreated patients with MBC. Because
of the excellent tolerability of nab-paclitaxel in hypersensi-
tivity reactions to docetaxel and paclitaxel, we decided to
administer weekly nab-paclitaxel in a patient with locally
advanced breast cancer with skin toxicity secondary to de-
layed hypersensitivity to taxanes. No skin toxicity occurred,
which allowed us to complete neoadjuvant treatment.
In 2009, Gradishar et al. performed a randomized Phase
II study with 302 patients with previously untreated MBCrticle albumin-bound paclitaxel.
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tients who either received nab-paclitaxel 300mg/m2 every
3 weeks, 100mg/m2 weekly or 150mg/m2 weekly, or doce-
taxel 100mg/m2 every 3 weeks. The two weekly regimens
demonstrated a longer progression-free survival in an in-
dependent review, although this was not confirmed by the
investigators for the 100mg/m2 dose. Peripheral neur-
opathy was similar, but shorter in duration with nab-
paclitaxel [16]. We chose nab-paclitaxel 100mg/m2 weekly
based on the results of this study and on the patient’s
neurotoxicity. In addition, this regimen (nab-paclitaxel
100mg/m2 weekly) has demonstrated the same antitumor
activity as the 125mg/m2 weekly regimen and a more fa-
vorable safety profile in patients with MBC that had
progressed with previous taxane therapy without severe
hypersensitivity reactions reported. Both doses have
exerted a good efficacy profile in heavily pretreated
taxane-refractory patients [4].
In this case report the pathological response was not
good, with persistence of malignancy locally and signifi-
cant axillary tumor burden. This might have been a re-
sult of the tumor biology and its advanced clinical stage
at diagnosis.
However, the patient could complete the treatment plan
within the scheduled timeframe with acceptable tolerance.
Nab-paclitaxel is expected to have only limited cross-
resistance to solvent-based taxanes [4].Conclusions
We conclude that nab-paclitaxel is a good therapeutic
option for patients with any breast cancer stage who
develop taxanes-induced skin toxicity.Consent
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